Hypoxia and Inflammatory Injury in Human Renovascular Hypertension
Status:
Completed
Trial end date:
2020-09-25
Target enrollment:
Participant gender:
Summary
Current treatments for ARAS based on restoring blood flow alone have been unsuccessful at
recovering kidney function. For this reason we are studying a stem cell product called
"mesenchymal stem cells" or MSC. Mesenchymal stem cells (MSC) are grown from a person's own
fat tissue (obtained as a fat biopsy) and infused back into the patient's own kidney.
This study is also being done to determine if the MSC infusion prior to percutaneous
transluminal renal angioplasty with stenting (PTRA) further enhances changes in single kidney
blood flow and restoration of kidney function, as well as to assess the relationship between
MSC dose and measures of kidney function.
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborators:
University of Alabama at Birmingham University of Mississippi Medical Center